Topical steroids in chronic inflammatory bowel disease;TOPISCHE STEROID BEI CHRONISCH-ENTZUNDLICHEN DARMERKRANKUNGEN

Internist

Volumn 38, Issue 12, 1997, Pages 1154-1159

  Fleig, W E ^a,b  

^a Klin und Poliklin F Inn Med I

^b MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; GLUCOCORTICOID; PREDNISOLONE; STEROID; ANTIINFLAMMATORY AGENT;

HUMAN; REVIEW; TOPICAL DRUG ADMINISTRATION; ULCERATIVE COLITIS; CROHN DISEASE; DOSE RESPONSE; DRUG ADMINISTRATION; LONG TERM CARE; RECTAL DRUG ADMINISTRATION;

ADMINISTRATION, RECTAL; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; COLITIS, ULCERATIVE; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HUMANS; LONG-TERM CARE;

EID: 0031437772     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050127     Document Type: Review

References (32)

1. Truelove SC, Witts LJ (1955) Cortisone in ulcerative colitis. Br Med J II:1041-1048
2. Turelove SC (1958) Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium: a report on a controlled therapeutic trial. Br Med J II:1072-1077
3. Truelove SC, Witts LJ (1959) Cortisone and corticotropin in ulcerative colitis. Br Med J I:387-394
4. Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, Singleton JW (1979) National cooperative Crohn's disease study: Results of drug treatment. Gastroenterology 77:847-859
5. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H (1984) European cooperative Crohn's disease study (ECCDS): Results of drug treatment. Gastroenterology 86:249-266
6. Brattsand R (1990) Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 4:407-414
7. Schölmerich J, Andus T (1995) Old and new steroids. In: Fleig WE (Hrsg) Inflammatory bowel disease. Kluwer Academic Publishers, Lancaster, 193-224
8. Thiesen A, Thomson ABR (1996) Review article: older systemic and newer topical glucocorticosteroids and the gastrointestinal tract. Aliment Pharmacol Ther 10:487-496
9. Juniem JL (1988) Pharmacology of tixocortol pivalate, a glucocorticoid belonging to the 21-thlosteroid family. First Meeting 21-thiosteroids. Mediators of inflammation. The Local Response. S 65-70
10. Chanoine F (1988) Tixocortol pivalate: Pharmacokinetics and metabolism. First Meeting 21-thiosteroids. Mediators of inflammation.The Local Response. S. 71-82
11. Axelsson B, Brattsand R, Anderson PH, Ryrfeldt A, Thalen A (1984) Relationship between glucocorticosteroid effects of bedomethasone 17α, 21-dipropionate, beclomethasone 17α-propionate and beclomethasone as studies in human, mouse and rat tissue. Respiration 46 (Suppl 1):4
12. Greenberg GR (1994) Budesonide for the treatment of inflammatory bowel diesease. Can J Gastroenterol 8:369-372
13. Ryrfeldt A, Andersson P, Edsbäcker S, Tonnesson M, Davies D, Pauwels R (1982) Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Resp Dis Suppl. 122:86-95
14. Nyman-Pantelidis M, Nilsson A, Wagner ZG, Borga O (1994) Pharmacokinetics and retrograde colonic spread of budesonide enemas in patients with distal ulcerative colitis. Aliment Pharmacol Ther 8:617-622
15. Danielsson A, Löfberg R, Persson T, Salde L, Schiöler R, Suhr O, Willen R (1992) A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol 27:9-12
16. Löfberg R, Ostergaard Thomsen O, Langholz E, Schiöler R, Danielsson A, Suhr O, Graffner H, Pahlmann L, Matzen P, Moller-Petersen JF, Halvorsen L, Hovdenak N, Willen R, Persson T, Seidegard C (1994) Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 8:623-629
17. Thomsen O, Andersen T, Langholz E, et al. (1994) Lack of adrenal gland suppression with budesonide enema in active distal ulcerative colitis: a prednisolone-controlled 8-week study. Eur J Gastroenterol Hepatol 6:507-511
18. Edsbäcker S, Larsson P, Nilsson M, et al. (1995) Budesonide controlled ileal release (CIR) capsules affect plasma cortisol less than prednisolone (Abstract). Gastroenterology 108:A832
19. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, Williams CN, Nilsson LG, Persson T, Canadian Inflammatory Bowel Disease Study Group (1994) Oral budesonide for active Crohn's disease. N Engl J Med 331:836-841
20. Rutgeerts P, Löfberg R, Malchow H, Lamers C, Olaison G, Jewell D, Danielsson A, Goebell H, Ostergaard Thomsen O, Lorenz-Meyer H, Hodgson H, Persson T, Seidegard C (1994) A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 331:842-845
21. Löfberg R, Rutgeerts P, Malchow H, Lamers C, Danielsson A, Olaison G, Jewell D, Ostergaard Thomsen O, Lorenz-Meyer H, Goebell H, Hodgson H, Persson T, Seidegard C (1996) Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A Placebo controlled one year study. Gut 39:82-86
22. Mulder CJJ, Fockens P, Meijer JWR, van der Heide H, Wiltink EHH, Tytgat GNJ (1996) Bedomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 8:549-553
23. Löfberg R, Danielsson A, Suhr O, Nilsson A, Schiöler R, Nyberg A, Hultcrantz R, Kollberg B, Gillberg R, Willén R, Persson T, Salde L (1996) Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 110:1713-1718
24. Gross V, Caesar I, Andus T, Vogelsang H, Adler G, Malchow H, Weber A, Gierend M, Schölmerich J, German/Austrian Budesonide Study Group (1997) Dose-finding study with oral budesonide in patients with active Crohn's ileocolitis (Abstract). Gastroenterology 112:A986
25. Caesar I, Gross V, Roth M, Andus T, Schmidt C, Raedsch R, Weber A, Gierend M, Ewe K, Schölmerich J, members of the German Budesonide Study Group (1995) Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Z Gastroenterol 33:247-250
26. Novacek G, Kleinberger M, Vogelsang H, Moser G, Lochs H (1995) Budesonide in glucocorticoid dependent chronic active Crohn's disease: a pilot study. Z Gastroenterol 33:251-254
27. Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, Schulz HJ, Bär U, Weber A, Gierend M, Ewe K, Schölmerich J, the German/Austrian budesonide study group (1996) Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. Eur J Gastroenterol Hepatol 8:905-909
28. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, Williams CN, Nilsson LG, Persson T, Canadian Inflammatory Bowel Disease Study Group (1996) Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study. Gastroenterology 110:45-51
29. Stange EF, Schreiber S, Raedler A, Stallmach A, Schölmerich J, Loeschke K, Starlinger M, Fischbach W, Caspary WF, für die Konsensuskonferenz (1997) Therapie des Morbus Crohn. Z Gastroenterol 35:541-554
30. Tarpila S, Turunent U, Seppala K, et al. (1994) Budesonide enema in active haemorrhagic proctitis - a controlled trial against hydrocortisone foam enema. Aliment Pharmacol Ther 8:617-622
31. Bianchi Porro G, Prantera C, Campiere M, et al. (1994) Comparative trial of methylprednisolone and budesonide enemas in active distal ulcerative colits. Eur J Gastroenterol Hepatol 6:125-130
32. Lémann M, Galian A, Rutgeerts, van Heuverzwijn R, Cortot A, Viteau JM, Elewaut A, Belaiche J, Froguel E, Modigliani R (1995) Comparison of budesonide and 5-amino-salicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 9:557-562